Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL114868 | 1.00 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL114606 | 1.00 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL27156438 | 1.00 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL26059206 | 0.88 | CHRM2 (0.42) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL1178180 | 0.85 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL8199039 | 0.85 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL653778 | 0.85 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL2567234 | 0.85 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL14428300 | 0.85 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL22220554 | 0.83 | NR1H2 (0.42) | NR1H2CHRM2CHRM1CHRM3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-114096532-B | Heterocyclic compounds which inhibit tyrosine kinase 2 activity | 广州诺诚健华医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-115124538-A | Bicyclic compounds as ATX inhibitors | 豪夫迈·罗氏有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2022197641-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-AMINE DERIVATIVES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS AND/OR INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | RAPT THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| CN-107635995-B | Bicyclic compounds as ATX inhibitors | 豪夫迈·罗氏有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114096532-A | Heterocyclic compounds inhibiting tyrosine kinase 2 activity | 广州诺诚健华医药科技有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-107614505-B | Novel bicyclic compounds as dual ATX/CA inhibitors | 豪夫迈·罗氏有限公司 | 2021-05-07 | — | — | CN | disclosed |
| EP-2486005-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8288404-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2486005-A1 | PYRROLIDINE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044073-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | DCK, MCL1, DTYMK | NR1H2 3017/4885CHRM2 4852/4885CHRM1 4811/4885 |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | DCK, MCL1, DTYMK | NR1H2 3017/4885CHRM2 4852/4885CHRM1 4811/4885 |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | NR1H2 160/4885CHRM2 559/4885CHRM1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.